

AD _____

AD-A196 901

PRIMARY SCREENING OF POTENTIAL RADIOPROTECTIVE AGENTS

ANNUAL / FINAL REPORT

CURTIS P. SIGDESTAD, PH.D.

31 March 1988

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND

Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD 17-86-C-6229

**University of Louisville School of Medicine
Louisville, Kentucky 40292**

Approved for public release, distribution unlimited.

DTIC
ELECTE
JUN 20 1988
S
E

The findings of this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

88 6 52 0 52

AD-A196901

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED		1b. RESTRICTIVE MARKINGS	
2a. SECURITY CLASSIFICATION AUTHORITY		3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for Public Release Distribution Unlimited	
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE		5. MONITORING ORGANIZATION REPORT NUMBER(S)	
4. PERFORMING ORGANIZATION REPORT NUMBER(S)		7a. NAME OF MONITORING ORGANIZATION	
6a. NAME OF PERFORMING ORGANIZATION University of Louisville School of Medicine	6b. OFFICE SYMBOL (If applicable)	7b. ADDRESS (City, State, and ZIP Code)	
6c. ADDRESS (City, State, and ZIP Code) Louisville, Kentucky 40292		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-86-C-6229	
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command	8b. OFFICE SYMBOL (If applicable)	10. SOURCE OF FUNDING NUMBERS	
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012		PROGRAM ELEMENT NO. 62734-A	PROJECT NO. 3MI-62734A875
		TASK NO. BC	WORK UNIT ACCESSION NO. 086
11. TITLE (Include Security Classification) (U) Primary Screening of Potential Radioprotective Agents			
12. PERSONAL AUTHOR(S) Sigdestad, C.P.			
13a. TYPE OF REPORT Annual/Final	13b. TIME COVERED FROM 9/30/86 TO 3/15/88	14. DATE OF REPORT (Year, Month, Day) 1988 March 31	15. PAGE COUNT 59
16. SUPPLEMENTARY NOTATION Annual covers period 30 September 1987 - 15 March 1988			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	Radiobiology, Radiation Protective Agents, Low LET	
06	03	Radiation, Protectors, Mice, Drug Development,	
06	15	Drug Effects	
19. ABSTRACT (Continue on reverse if necessary and identify by block number) This report deals with primary screening of potential radiation protective agents. The drugs to be tested were provided by the U.S. Army Medical Research and Development Command, Fort Detrick, Maryland. The compounds were tested in toxicity screens to determine the maximum tolerated dose (MTD) effects. Limited available drug amounts precluded more refined testing. The second screen involved Cobalt-60 gamma radiation. The agents to be tested were injected intraperitoneally into CDI female Swiss mice, thirty minutes prior to irradiation with either 9.0 or 9.5 Gy. The latter value was found to be the radiation LD100(30) for this mouse strain. Survival was measured and the degree of protection was determined. Dose modification factors were determined on a limited number of agents as directed by the COR.			
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ☒ UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT. ☐ DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION Unclassified	
22a. NAME OF RESPONSIBLE INDIVIDUAL Marv Frances Postian		22b. TELEPHONE (Include Area Code) (301) 663-7325	22c. OFFICE SYMBOL SGRD-RMI-S

SUMMARY

This final report summarizes one and one-half year of research involving primary screening of potential radiation protective agents. The drugs to be tested were provided by the U. S. Army Medical Research and Development Command, Fort Detrick, Maryland. The compounds were tested in toxicity screens to determine the maximum tolerated dose (MTD) which was defined as the highest dose that produces no lethal effects. Limited available drug amounts precluded more refined testing. The second screen involved Cobalt-60 gamma radiation. The agents to be tested were injected intraperitoneally into CD1 female Swiss mice, thirty minutes prior to irradiation with either 9.0 or 9.5 Gy. The latter value was found to be the radiation LD100(30) for this mouse strain. Survival was measured and the degree of protection was determined.

Dose modification factors were determined on a limited number of agents as directed by the COR. (174)



Accession For	
NTIS GRA&I	☒
DTIC TAB	☒
Unannounced	☐
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

FOREWORD

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

TABLE OF CONTENTS

	PAGE
SUMMARY	1
FOREWORD	2
INTRODUCTION	6
MATERIALS AND METHODS	6
1. Animals	6
2. Test Drugs	7
3. Drug Toxicity Studies	14
4. Irradiation Procedures	14
A. Control Mice: Radiation Sensitivity	15
B. Radiation Protection Screens	15
C. Dose Modification Factors (WR-2721)	15
RESULTS AND DISCUSSION	15
1. Animals	15
2. Irradiated Unprotected Animals	15
A. Comparison of Irradiation Procedures	15
B. Gastrointestinal Death	16
C. Hematopoietic Death	22
3. WR-2721 Studies	26
A. Toxicity	26
B. Radiation Protection	26
C. Time of Injection	26
4. Toxicity Screening	33
5. Radioprotection Screening	33
6. Dose Modification Factor Determination	56
CONCLUSIONS	57
PUBLICATIONS	58
ACKNOWLEDGMENTS	58
DISTRIBUTION LIST	59

LIST OF TABLES

TABLE NUMBER	PAGE
1. List of Test Drugs	8
2. Seven Day Mortality after Cobalt-60 Irradiation	22
3. Thirty Day Lethality after Cobalt-60 Irradiation	23
4. Thirty Day Lethality after Cobalt-60 Irradiation	23
5. Thirty Day Lethality after Cobalt-60 Irradiation	26
6. Dose Modification by WR-2721	28
7. DMF of WR-2721	30
8. Time of Injection	32
9. Toxicity Screens	34
10. Distribution of Maximum Tolerated Doses for Test Agents	43
11. WR Drugs and Resultant Percent Survival	45
12. Radioprotection Screen	46
13. Thirty Day Lethality in WR-3689 Protected Mice	56
14. Thirty Day Lethality in WR-255591 Protected Mice	57

LIST OF FIGURES

FIGURE NUMBER	PAGE
1. 9.0 Gy Survival: Restricted vs Unrestricted	17
2. 9.5 Gy Survival: Restricted vs Unrestricted	18
3. 10 Gy Survival: Restricted vs Unrestricted	19
4. ^{60}Co Survival Time: Restricted	20
5. ^{60}Co Survival Time: Unrestricted	21
6. ^{60}Co Survival Time	24
7. ^{60}Co Survival Time	25
8. ^{60}Co Survival Time	27
9. WR-2721 Protection	31

INTRODUCTION

The Armed Forces of the United States have a mandate to provide health services to its members. This includes prophylactic care for numerous conditions of which the protection from ionizing radiation is only one. The U. S. Army has spearheaded the search for effective anti-radiation drugs since the first description that an agent can protect animals from the adverse effects of x-rays. It has been through their efforts that the development of WR-2721 has been shown to be the most effective protector. This benchmark protector is, however, not entirely optimal, inasmuch as it shows some toxicity, is effective only for a few hours, does not pass the blood-brain barrier, and it is not well absorbed when taken orally. For these reasons the search goes on for better protectors which will provide the needed protection for military personnel in the event of having to perform their duties in an environment that will likely expose them to levels of ionizing radiation which will be detrimental to their well being.

This report describes the initial testing of potential radiation protective agents. It reports results on toxicity determinations, radiation effectiveness screens and studies in some depth the better protectors identified.

MATERIALS and METHODS

1. Animals:

The animals used in the toxicity and radioprotection screens were viral antibody free (VAF) CD1 Swiss female mice. They are obtained from Charles Rivers Laboratories and shipped from their Portage, Michigan facilities. Animals are delivered in filtered crates to the University's Animal Care Center. Upon receipt the animals are examined and any sign of ill health is reported immediately before any of the animals are caged. Mice are housed 5 to a cage and are kept for 14 days before being used in experimental trials. The cages are placed on racks in a laminar

flow unit. The animals are kept on a 12 hr light cycle, they are fed Purina Lab Chow 5010 ad libitum and are maintained on hyperacidified water (pH 2.7) to inhibit the growth of Pseudomonas species.

Serological monitoring for Sendai, PVC, MHV and Mycoplasma is routinely performed by the vendor and repeated by the Veterinary staff upon receipt and at weeks one and two after arrival. Standard bacteriological sampling is part of the quality control program. Animal care personnel are outfitted with shoe covers, disposable gowns, caps, masks and gloves when handling the animals. The animal housing facility, cages, water bottles, bedding material and feed are subjected to a strict regimen of sanitation and sterilization procedures.

Animals surviving the thirty day test period are disposed of by means of Carbon dioxide euthanasia under conditions described in the "Guide for Laboratory Animal Facilities and Care".

2. Test Drugs:

The compounds to be tested in the toxicological and radioprotection screening are supplied by the U. S. Army Medical Research and Development Command. Technical support is provided by the Contracting Officers Representative (COR) at the Walter Reed Institute for Research. Table one lists the drugs submitted for testing along with the submitters.

In order to avoid possible degradation of the test agents extreme care is taken to provide optimal storage conditions. Upon receipt the drugs are immediately stored according to the instructions provided on the accompanying data sheets. They are kept under desiccation with Drierite either in a refrigerator or freezer. Possible photodegradation is minimized by storage in amber bottles and avoiding direct exposure to light. Before testing the compounds are allowed to equilibrate to room temperature. The drugs are weighed and dissolved or suspended in a suitable vehicle immediately before injection. Drugs soluble in water are dissolved in sterile, nonpyrogenic water for injection.

LIST OF TEST DRUGS

TABLE ONE

SUBMITTER	WR	COMPOUNDS
Lamar Field Vanderbilt Univ.	253179	Disodium (1,2-Ethylenebis(dithio)bis-(4-butanedisulfinate) $C_{10}H_{20}O_4S_6 \cdot 2Na$
Lamar Field Vanderbilt Univ.	255650	Disodium (1,4-Butylene bis dithio) bis (5-pentanesulfinate) $0.4 H_2O$ $C_{14}H_{28}Na_2O_4S_6 \cdot 0.4 H_2O$
Lamar Field Vanderbilt Univ.	255652	Disodium 5,5'-Trithio bis(pentanesulfinate) $0.25 H_2O$ $C_{10}H_{20}Na_2O_4S_5 \cdot 0.25 H_2O$
Lamar Field Vanderbilt Univ.	256822	cis-1,4-bis(2-aminoethylthio)-2-butene Dihydrochloride $C_8H_{20}N_2S_4Cl_2$
Lamar Field Vanderbilt Univ.	255541	Sodium 3(p-tolyldithio)propanedisulfinate $C_{10}H_{13}O_2S_3 \cdot Na$
Lamar Field Vanderbilt Univ.	255542	Disodium(1,4-butylene bis dithio)bis(3-propanedisulfinate) $C_{10}H_{20}O_4S_6 \cdot 2Na \cdot H_2O$
Lamar Field Vanderbilt Univ.	255544	Disodium 3,3'trithio bis (propanedisulfinate) $2x (C_6H_{12}O_4S_5) \cdot 4Na \cdot 3 \cdot H_2O$
Ludwig Bauer U.of Illinois	254353	S-[N(2-[1-(4-Fluorophenyl)-2-adamantyl]ethyl)carbamidinium]methyl phosphorothioate Monohydrate $C_{20}H_{28}FN_2O_3PS \cdot H_2O$

TABLE ONE Cont.

SUBMITTER	WR	COMPOUNDS
Ludwig Bauer U.of Illinois	254593	S-(N-[2(2-Phenyl-1-adamantyl)ethyl]carbamidinium)methyl} phosphorothioate $C_{20}H_{29}N_2O_3PS$
A.L.Ternay U.of Texas	254407	L-cysteine cysteamine disulfide Hydrochloride $C_5H_{12}N_2O_2S_2 HCl$
A. L. Ternay U. of Texas	254844	Cysteaminyl Thioepiandrosteryl Disulfide Hydrochloride $C_{21}H_{35}NOS_2 HCl$
A.L. Ternay U. of Texas	255612	2-Mercaptophenothiazine $C_{12}H_9NS_2$
A. L. Ternay U. of Texas	256107	Cysteamyl 2-(3amino-propylamino)ethyl disulfide Trihydrochloride $C_7H_{19}N_3S_3 \cdot 3HCl$
A. L. Ternay U. of Texas	256234	2-(3-aminopropylamino) ethyl 2-hydroxyethyl disulfide Dihydrochloride $C_7H_{18}N_2OS_2 \cdot 2HCl$
Ash Stevens, Inc.	2721	S-2-Aminopropylamino) ethyl phosphorothioic acid Trihydride $C_5H_{15}N_2O_3PS \cdot 3H_2O$
Ash Stevens, Inc.	1065	2-(3-Aminopropylamino) ethyl Mercaptan Dihydrochloride $C_5H_{14}N_2S \cdot 2 HCl$
Ash Stevens, Inc.	151327	S-3-(3-Methylaminopropylamino) propylphosphorothioic Acid Trihydrate $C_7H_{19}N_2O_3PS \cdot 3H_2O$

TABLE ONE Cont.

SUBMITTER	WR	COMPOUNDS
Ash Stevens, Inc.	254677	S-[2-(3-Aminopropylamino)ethylthio]-L-cysteine Dihydrochloride $C_8H_{19}N_3O_2S_2 \cdot 2HCl$
Ash Stevens, Inc.	255549	2-(3-Aminopropylamino)ethylsulfinic acid Hydrochloride $C_5H_{14}N_2O_2S \cdot 2HCl$
Ash Stevens, Inc.	255591	2-[(3-Methylaminopropyl)amino]ethanethiol Dihydrochloride $C_6H_{16}N_2S \cdot 2HCl$
Ash Stevens, Inc.	151326	3-(3-Methylaminopropylamino)propyl Mercaptan Dihydrochloride $C_7H_{18}N_2S \cdot 2HCl$
F. I. Carroll	254638	S-2-(2'-Thiocarbamidoethylamino)ethyl Lithium Hydrogen Phosphorothioate Trihydrate $C_5H_{12}N_2O_3PS_2 \cdot Li \cdot 3H_2O$
F. I. Carroll	254676	S-2-(2'-Amidinoethylamino)ethylphosphorothioic Acid Hemihydrate $2x C_5H_{14}N_3O_3PS \cdot H_2O$

TABLE ONE Cont.

SUBMITTER	WR	COMPOUNDS
F. I. Carroll	254721	S - 2 (2 ' - N - M e t h y l - amidinoethylamino)ethyl- phosphorothioic Acid Trihydrate $C_6H_{16}N_3O_3PS \cdot 3H_2O$
F. I. Carroll	255830	S - 2 [2 ' - (4 , 5 - Dihydroimidazolyl)ethyl- amino]ethyl Lithium Hydrogen Phosphorothioate Hydrate $C_7H_{15}N_3O_3PS \cdot Li \cdot H_2O$
F. I. Carroll	256281	S - 2 - (2 ' - t e r t - butylcarbamoylethylamino) ethyl Dilithium Phosphorothioate Hemihydrate $2x C_9H_{19}N_2O_4PS \cdot 4Li \cdot H_2O$
F. I. Carroll Research Triangle Institute	256706	S - 2 - (3 ' - Amidinopropylamino) ethyl-phosphorothioic Acid. Hydrate $C_6H_{16}N_3O_3PS \cdot H_2O$
F. I. Carroll Research Triangle Institute	257614	4-(3-Methylaminopropyl)- 5,6-Dihydro-1,2,4-3(4H) Dithiazinethione Hydrochloride $C_7H_{14}N_2S_3 \cdot HCl$
James C. Piper Southern Research Institute	255538	S , S ' - 2 - (3 - Methylaminopropylamino)- trimethylenebis(phos- phorothioic Acid) Monohydrate $C_7H_{20}N_2O_6P_2S_2 \cdot H_2O$

TABLE ONE Cont.

SUBMITTER	WR	COMPOUNDS
James C. Piper Southern Research Institute	255709	1-([3-(3-aminopropyl)] thiazolidin-2-yl)-D- gluco-1,2,3,4,5-pentane- pentol Dihydrochloride $C_{11}H_{24}N_2O_5S \cdot HCl$
James C. Piper Southern Research Institute	255758	N-(3-Aminopropyl)-2,2'- Iminodi(S-ethyl dihydrogen Phosphorothioate) Hemiethanolate dihydrate $C_7H_{20}N_2O_6P_2S_2 \cdot 0.5 C_2H_5OH$ $\cdot H_2O$
James C. Piper Southern Research Institute	257172	S, S' - [3 - (3 - Aminopropylamino)pen- tamethylene]bis (thioacetate) dihydrobromide $C_{12}H_{24}N_2O_2S_2 \cdot HBr$
James C. Piper Southern Research Institute	257623	S-3-(3-Methylamino- propylamino)propyl Thioacetate Dihydrobro- mide $C_9H_{20}N_2OS \cdot 2HBr$
Klayman/Scoville	3689	S-[2-(Methylaminopropyl) aminoethyl]phosphoro- thioic Acid Monohydrate $C_6H_{17}N_2O_3PS \cdot H_2O$
Southwest Research Institute	255796	2-(3-Aminopropylamino) ethane sulfonic Acid Hydrochloride $C_5H_{14}N_2O_3S \cdot HCl$

TABLE ONE Cont.

SUBMITTER	WR	COMPOUNDS
Sigma Company	015443	α -Ketoglutaric Acid Crystalline Monosodium Salt $C_5H_5O_5 Na$
W. O. Foye	254115	$C_{20}H_{25}N_2S$ I

Drugs which are found to be insoluble in water are suspended 0.3% methylcellulose, 15% ethanol and water or as indicated on the data sheet. The drug amount is formulated so that injections are administered at 1% of individual body weight. The acidity of the highest injected dose is measured and recorded. All drug doses mentioned represent the free base weight and are corrected for salt and water content of the individual compounds. The drugs are administered by intraperitoneal injection thirty minutes prior to irradiation.

3. Drug Toxicity Studies:

Groups of 5 to 10 mice are injected i.p. with the test agent. At least three doses are used to determine the highest dose that results in 100% survival which is considered the maximum tolerated dose (MTD).

4. Irradiation Procedures:

An Atomic Energy of Canada (AECL) Therac 780 Cobalt Teletherapy unit is used as a radiation source for all radiation protection testing. The dose rate is 1.1 Gy/minute at a Source to Surface Distance (SSD) of 78.5 cm. The surface field size is 35 x 35 cm and the backscatter factor is determined to be 1.084. Dosimetry is performed by the Departmental radiological physics staff using a Victoreen Condenser R Meter with additional Thermoluminescence dosimetry (TLD).

The animal holder is placed on an electric device which rotates animals at about 4 rpm in the irradiation field. This procedure assures a uniform dose delivered to each mouse and corrects for any field flatness problems.

Originally, the mice were allowed to freely move in a well ventilated leucite cylindrical container 30 cm in diameter and 4 cm high. Ultimately a animal holding device with the same dimensions but divided into twelve individual compartments is utilized. This provides greater precision in individual mouse dosimetry.

A. Control Mice: Radiation Sensitivity

Unprotected mice were extensively studied to determine baseline radiation sensitivity. This included Probit Analysis for six and thirty day mortality which reflects gastrointestinal and hematopoietic related deaths respectively.

B. Radiation Protection Screens:

Assays of radiation protection utilize drug doses at the maximum tolerated dose (MTD), one-half the MTD and one-fourth the MTD. Ten mice are each injected i.p. with the appropriate dose and irradiated with a dose which assures 100% lethality of control, unprotected mice. Survival is followed for thirty days.

C. Dose Modification Factors:

Probit Analysis is applied in the determination of the dose modification factor (DMF). Six radiation doses, which are expected to bracket the LD50, are selected at an equal log interval. Mice are either injected i.p. with the test agent or its solvent (control, unprotected) and irradiated whole-body thirty minutes later. Survival is determined for thirty days post irradiation. DMFs are determined by multiple probit analysis which results in a potency ratio with 95% confidence limits.

RESULTS and DISCUSSION

1. Animals:

Cultures from mouth, eye and sipper tubes were taken, periodically, to determine whether pathogenic bacteria were modifying the response to irradiation. In addition, sterile blood cultures were obtained before and after drug or radiation treatment. The results indicated that there was no contamination of pathogenic organisms, specifically Pseudomonas. Blood cultures were sterile and blood counts did not indicate an infection.

2. Irradiated, Unprotected Test Animals:

A. Comparison of Irradiation Procedures:

This experiment was performed because the original

irradiation procedure allowed mice to roam free in a leucite chamber while being rotated in the gamma beam. The mice were observed to crawl over one another or 'pile up' at the edge of the container. This presented dosimetry problems which could add scatter to the data. A comparative study was designed to test if irradiation in a container with individual compartments improved the precision from the original procedure. The 30-day lethality of unrestricted and restricted animals at either 9.0, 9.5 or 10 Gy was compared. Figures 1-3 compare the three doses individually, while figures 4-5 compare restricted vs. unrestricted for all doses tested.

Mice irradiated with a dose of 9 Gy showed 20% survival when animals were allowed to roam free in the irradiation chamber. As the dose increased to 9.5 Gy this difference was abolished. A second important finding is seen in figure 3, where 10 Gy was administered. Here it can be noticed that gastrointestinal death is definitely included at this dose level. Early deaths between days 5 and 7 should be considered gut related.

Figures 4-5 compare survival time of irradiated restricted or unrestricted test animals at all doses. When mice were irradiated in the restricted container 100% lethality was noted at all three radiation doses, while unrestricted mice showed 20% survival at 9.0 Gy. As in the previous figures the inclusion of gastrointestinal syndrome was noted with 10.0 Gy.

B. Gastrointestinal Death:

Initial studies to determine the sensitivity of the gastrointestinal epithelium of the CD1 female mouse were performed. Table 2, shows the results of these studies. The lethal dose to 50% of the mice was found to be 12.77 ± 0.3 Gy. The resultant probit curve was linear with a probability of 99.8%.




FIGURE 1. Survival time of CD1 female mice after irradiation with 9.0 Gy Cobalt-60 gamma irradiation. Open circles represent animals which were allowed to run free in the irradiation device. Closed circles show survival of mice irradiated in individual chambers in the irradiation device apparatus.

9.5 Gy Survival: Restricted vs. Unrestricted




FIGURE 2. Survival time of CD1 female mice after irradiation with 9.5 Gy Cobalt-60 gamma irradiation. Open circles represent animals which were allowed to run free in the irradiation device. Closed circles show survival of mice irradiated in individual chambers in the irradiation device apparatus.




FIGURE 3. Survival time of CD1 female mice after irradiation with 10.0 Gy Cobalt-60 gamma irradiation. Open circles represent animals which were allowed to run free in the irradiation device. Closed circles show survival of mice irradiated in individual chambers in the irradiation device apparatus.




FIGURE 4. Survival time of CD1 female mice after irradiation with 9.0 (open circles), 9.5 (closed circles) or 10.0 (open triangles) Gy Cobalt-60 gamma irradiation under restricted conditions. Note at 10 Gy dose early gut-related deaths observed.




FIGURE 5. Survival time of CD1 female mice after irradiation with 9.0 (open circles), 9.5 (closed circles) or 10.0 (open triangles) Gy Cobalt-60 gamma irradiation under unrestricted conditions. Note at 10 Gy dose early gut-related deaths observed.

TABLE 2
Seven Day Mortality after Cobalt-60 Irradiation

Dose (Gy)	n	Lethality	Percent
Exp 87-8			
11.17	15	3	20
12.29	15	4	27
13.52	15	8	53
14.88	15	8	53
16.36	15	15	100
LD ₅₀ (7) = 12.77 ± 0.33 Gy		Linearity = 99.8%	

C. Hematopoietic Death:

Three determinations of the LD₅₀(30) were performed during the contract year. The initial study which tested only 10 mice per dose resulted in a LD₅₀ of 7.19 Gy which was apparently a low estimate of this value. Table 3, shows the results of this experiment, and figure 6 depicts the survival times for the six highest radiation doses used in this study.

The second study in this series utilized 22 mice per point and gave results which appear more probable. The LD₅₀ was found to be 7.92 ± 0.05 Gy (Table 4). Figure 7 shows the survival time of mice after various radiation doses. This correlated well with the third experiment the results of which are shown in Table 5 and Figure 8. The LD₅₀ was found to be 7.73 ± 0.07 Gy which is not statistically significantly different from the second study.

TABLE 3
Thirty Day Lethality after Cobalt-60 Irradiation

Dose (Gy)	n	Lethality	Percent
Exp 86-2			
5.75	10	0	0
6.61	10	0	0
7.60	10	8	80
8.74	10	10	100
10.05	10	10	100
11.56	10	10	100
13.30	10	10	100
LD ₅₀ (30) = 7.19 Gy $\pm$ 0.37 Gy		Linearity - 99.59%	

TABLE 4
Thirty Day Mortality after Cobalt-60 Irradiation

Dose (Gy)	n	Lethality	Percent
Exp 87-14			
6.00	22	0	0
6.60	22	0	0
7.26	22	2	9
7.98	22	14	64
8.78	22	20	91
9.66	22	22	100
LD ₅₀ (30) = 7.92 $\pm$ 0.08 Gy		Linearity = 84.5%	




FIGURE 6. Survival time of CD1 female mice after irradiation with doses ranging from 6.6 to 13.3 Gy Cobalt-60 gamma irradiation. Ten mice were used per dose which was insufficient for good statistics.




FIGURE 7. Survival time of CD1 female mice after irradiation with doses ranging from 6.6 to 9.6 Gy Cobalt-60 gamma irradiation. Twenty-two mice were used per dose which better precision in the data.

TABLE 5
Thirty Day Lethality after Cobalt-60 Irradiation

Dose (Gy)	n	Lethality	Percent
Exp 87-16			
6.21	24	0	0
7.02	24	5	21
7.93	36	22	61
8.96	24	21	88
10.13	12	12	100
LD ₅₀ (30) = 7.73 Gy $\pm$ 0.07 Gy		Linearity - %	

3. WR-2721 Studies

A. Toxicity

Mice were injected i.p. with WR-2721 in doses which ranged from 737 to 1107 mg/kg (base). Probit analysis indicated a LD₅₀ of 972 mg/kg. Subsequent experiments used 600 mg/kg base as WR-2721 benchmark studies.

B. Radiation Protection with WR-2721:

Dose modification factors were determined for four drug doses: 150, 300, 476 and 600 mg/kg base. The results are shown in Figure 9 and in Table 6-7.

C. Time of Injection:

Mice were injected with WR-2721 (600 mg/kg, base) at 5, 15, 30, 45, 60 and 90 minutes and 3, 6, 12, 24 and 48 h prior to irradiation with Cobalt-60 gamma rays. A dose of 12 Gy was selected to assure lethality when protection was minimal. This dose of WR-2721 afforded 100% survival as early as 5 minutes prior to irradiation. This level of protection continued for injection times up to and including 90 minutes. At three hours, however, protection was reduced to 80% and at 6 hours, no protection was noted (Table 8). If a lower radiation dose would have been used, perhaps, protection would have been extended beyond the three hour time interval noted in these experiments.




FIGURE 8. Repeat of experiment shown in Figure 7. Survival time of CD1 female mice after irradiation with doses ranging from 6.6 to 9.6 Gy Cobalt-60 gamma irradiation. Twenty-two mice were used per dose which better precision in the data.

TABLE 6
DOSE MODIFICATION BY WR-2721

DOSE (mg/kg)	RADIATION Dose (Gy)	SURVIVORS	PERCENT	LD ₅₀ (%)	95% CL
0				7.83	7.79- 7.88
150	9.76	9/10	90	11.67	11.41- 11.94
	10.74	5/9	56		
	11.82	6/10	60		
	13.00	2/10	20		
	14.30	0/10	0		
	15.73	0/10	0		
	17.30	0/10	0		
300	13.22	10/10	100	19.06	18.00- 23.00
	14.55	9/10	90		
	16.00	10/10	100		
	17.60	9/10	90		
	19.36	4/10	40		
	21.29	0/10	0		
476	13.63	14/15	93	20.21	19.67- 20.74
	15.00	15/15	100		
	16.50	15/15	100		
	18.15	0/15	0	Spurious Deaths	
	19.97	15/15	100		
	21.96	6/15	33		
	24.16	2/15	13		
	26.57	1/15	7		
	29.23	0/15	0		

TABLE 6 (Cont.)

DOSE MODIFICATION BY WR-2721 (Cont.)

DOSE (mg/kg)	RADIATION Dose (Gy)	SURVIVORS	PERCENT	LD ₅₀ (%)	95% CL
600	20.00	13/15	87	23.80	23.65- 23.96
	22.00	13/15	87		
	24.20	7/15	47		
	26.62	2/15	13		
	29.28	0/15	0		
	32.21	0/15	0		

TABLE 7
DMF of NR2721

Dose		DMF	
mg/kg [Base]	LD50(30)	773 RAD*	792 RAD*
150	1167	1.51	1.47
300	1906	2.47	2.41
476	2020	2.61	2.55
600	2380	3.08	3.01

* Values used as the denominator of the DMF calculation as determined in Experiments 87-14 and 87-16.

WR-2721 PROTECTION




FIGURE 9. Dose modification factors as a function of drug dose. WR-2721 was injected i.p. into CDI female mice 30 minutes prior to Cobalt-60 gamma irradiation. The drug dose was corrected for base weight.

TABLE 8

TIME OF INJECTION

WR-2721 (600 mg/kg) and 12.0 Gy

TIME PRIOR TO IRRADIATION	30-DAY SURVIVORS	SURVIVAL PERCENT
5 Min	10/10	100
15 Min	10/10	100
30 Min	10/10	100
45 Min	10/10	100
60 Min	9/10	90 ¹
90 Min	10/10	100
3 Hr	8/10	80
6 Hr	0/10	0
12 Hr	0/10	0
24 Hr	0/10	0
48 Hr	0/10	0

¹Spurious Death

4. Toxicity Screening:

Thirty seven compounds were received from the USAMRDC for toxicity and radioprotection screening. Table 1 gives a detailed listing of these drugs and their submitters, respectively. The toxicity screening for these compounds have been completed and the data are presented in table 9.

Of these drugs seven (WR-254115; WR-254353; WR-254593; WR-257614; WR-254844; WR-255612 [BL-19593]; WR-257172) were found to be rather toxic with a maximum tolerated dose (MTD) of 37.5 mg/kg or less. Six of the tested agents were relative non-toxic with no lethalties observed at the 600 mg/kg, or higher, dose level (see table 10). The majority of the radioprotective agents had MTDs were in the range between 150 and 300 mg/kg [Base].

With three drugs: WR-254676 and the adamantyl-amidinium compounds WR-254353 and WR-254593 difficulties in dissolving or suspending them were encountered. Several vehicles containing varying ratios of Methylcellulose, Ethanol and Tween-80 were tried to improve the solubility of the above mentioned agents. However, none of the tested vehicles resulted in a homogeneous suspension. The results for these agents should, therefore, be judged with care. Agents WR-255612 (BL-19593 and BL-19584) and WR-254844 were dissolved in Dimethyl Sulfoxide (DMSO) and the injected volume was 0.5 percent of the body weight. These latter drugs, when injected ip, produced long-term toxic effects. This was manifested by listlessness and unthriftiness with toxic deaths occurring at times as late as 15 days post injection. One unusual toxic manifestation of the radioprotector WR-257614, was that it produced distention of the abdomen, which was a result of extensive ascites and bowel adhesions. This was found in 50% or more of the animals tested.

Another problem was noted, concerning the increase in toxicity in three drugs between the initial toxicity screening and the radioprotection testing, although all compounds were handled and stored with utmost care. For the drug WR-254593 the MTD decreased from 37.5 to 9.4 mg/kg; the MTD for WR-255830

TABLE 9
TOXICITY SCREENS

WR	BN	DOSE(mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
1065	BK 71365	1200 600 300 150 75	Water	i.p.	5/5 5/5 5/5 0/5 0/5	0/5 0/5 0/5 5/5 5/5	0 0 0 100 100
3689	BN 62848	1200 600 300	Water	i.p.	0/5 0/5 0/5	5/5 5/5 5/5	100 100 100
15443 34	BL 09435	1200 600 300	Water	i.p.	6/10 0/10 0/10	4/10 10/10 10/10	40 100 100
151326	BL 00101	300 250 200 150	Water	i.p.	3/5 1/5 1/5 0/5	2/5 4/5 4/5 5/5	40 80 80 100
151327	BK 98991	1200 600 300	Water	i.p.	5/5 0/5 0/5	0/5 5/5 5/5	0 100 100

13% Methyl Cellulose, 0.4% Tween-80, 15% Ethanol. 30.3% Methyl Cellulose, 15% Ethanol. 35% Sodium Bicarbonate.

TABLE 9 (cont.)

TOXICITY SCREENS

WR	BN	DOSE (mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
253179	BL 26909	300 250 150	Water	i.p.	1/5 0/5 0/5	4/5 5/5 5/5	80 100 100
254115	ZP 55243	75 37.5 18.75 9.38	see 1	i.p.	10/10 10/10 9/10 0/10	0/10 0/10 1/10 10/10	0 0 10 100
254353	ZP 55289	300 75 37.5 18.75	see 2	i.p.	5/5 5/5 5/5 0/5	0/5 0/5 0/5 5/5	0 0 0 100
254407	ZP 54399	1200 600 300	Water	i.p.	5/5 0/5 0/5	0/5 5/5 5/5	0 100 100

TABLE 9 (cont)

TOXICITY SCREENS

WR	BN	DOSE (mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
254593	ZP 55305	300 75 37.5 18.75	see 2	i.p.	5/5 5/5 0/5 0/5	0/5 0/5 5/5 5/5	0 0 100 100
254638	ZP 55467	750 600 300	Water	i.p.	5/5 3/5 0/5	0/5 2/5 5/5	0 40 100
254676	BL 08830	300 150 75	see 2	i.p.	2/10 1/10 0/10	8/10 9/10 10/10	80 90 100
254677	BL 08778	1200 600 300 150	Water	i.p.	10/10 10/10 5/10 0/10	0/10 0/10 5/10 10/10	0 0 50 100
254721	BL 09346	300 150 75	see 2	i.p.	5/10 0/10 0/10	5/10 10/10 10/10	50 100 100

TABLE 9 (cont.)

TOXICITY SCREENS

WR	BN	DOSE (mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
254844	BL 10849	150 100 50	DMSO	i.p.	4/5 4/5 2/5	1/5 1/5 3/5	20 20 60
255538	BK 40404	1200 600 300 150 75 37.5	see 3	i.p.	5/5 5/5 5/5 0/5 0/5 0/5	0/5 0/5 0/5 5/5 5/5 5/5	0 0 0 100 100 100
255541	BK 40468	300 150 75	Water	i.p.	5/5 4/5 0/5	0/5 1/5 5/5	0 20 100
255542	BK 40477	600 450 300	Water	i.p.	5/5 3/5 0/5	0/5 2/5 5/5	0 40 100

TABLE 9 (cont.)

TOXICITY SCREENS

WR	BN	DOSE (mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
255544	BK 40486	750 600 300	Water	i.p.	4/5 2/5 0/5	1/5 3/5 5/5	20 60 100
255549	BK 40780	1200 600 300	Water	i.p.	0/5 0/10 0/10	5/5 10/10 10/10	100 100 100
255591	BL 24405	1200 600 300 150 75	Water	i.p.	5/5 5/5 0/5 0/5 0/5	0/5 0/5 5/5 5/5 5/5	0 0 100 100 100
255612	BL 19593	200 150 75	DMSO	i.p.	4/5 3/5 1/5	1/5 2/5 4/5	20 40 80
255612	BL 19584	200 150 75	DMSO	i.p.	3/5 3/5 0/5	2/5 2/5 5/5	40 40 100

TABLE 9(cont.)

TOXICITY SCREENS

WR	BN	DOSE (mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
255650	BL 20176	300 250 150	Water	i.p.	5/5 5/5 0/5	0/5 0/5 5/5	0 0 100
255652	BL 20167	600 300 150	Water	i.p.	3/5 0/5 0/5	2/5 5/5 5/5	40 100 100
255709	BK 75176	1200 600 300 150 75	Water	i.p.	5/5 5/5 0/5 0/5 0/5	0/5 0/5 5/5 5/5 5/5	0 0 100 100 100
255758	BL 21520	300 250 150	Water	i.p.	4/5 1/5 0/5	1/5 4/5 5/5	20 80 100

TABLE 9 (cont.)

TOXICITY SCREENS

WR	BN	DOSE (mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
255796	BL 21977	1200 600 300	Water	i.p.	0/5 0/5 0/5	5/5 5/5 5/5	100 100 100
255830	BL 22358	1200 600 300 150	Water	i.p.	10/10 10/10 9/10 0/10	0/10 0/10 1/10 10/10	0 0 10 100
256107	BL 26892	300 150 75	Water	i.p.	10/10 10/10 0/10	0/10 0/10 10/10	0 0 100
256234	BL 27915	300 150 75 37.5	Water	i.p.	5/5 0/5 0/10 0/10	0/5 5/5 10/10 10/10	0 100 100 100

TABLE 9 (cont.)

TOXICITY SCREENS

WR	BN	DOSE (mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
256281	BL 28529	1200 600 300 150	Water	i.p.	10/10 10/10 0/10 0/10	0/10 0/10 10/10 10/10	0 0 100 100
256706	BL 34205	150 75 37.5	Water	i.p.	5/5 0/5 0/5	0/5 5/5 5/5	0 100 100
256822	BL 38123	300 250 150	Water	i.p.	5/5 2/5 0/5	0/5 3/5 5/5	0 60 100
257172	BL 43955	150 75 37.5 18.75	Water	i.p.	5/5 5/5 4/5 0/5	0/5 0/5 1/5 5/5	0 0 20 100
257614	BL 49073	150 75 37.5 18.75	Water	i.p.	5/5 5/5 1/5 0/5	0/5 0/5 4/5 5/5	0 0 80 100

TABLE 9 (cont.)

TOXICITY SCREENS

WR	BN	DOSE (mg/kg)	VEHICLE	ROUTE	LETHALITY	SURVIVAL	%
257623	BL	200	Water	i.p.	5/5	0/5	0
	49242	150			1/5	4/5	80
		100			0/5	5/5	100

TABLE 10
DISTRIBUTION OF MAXIMUM TOLERATED DOSE (mg/kg)
FOR TEST AGENTS

9.38	18.75	37.5	75	100	150	300	600	1200
254115	254353	254593 ¹	254676	257623	1065	254638	15443	3689 ¹
	257614	255612 ²	255107	255541	151326	255542	151327	255549
		254844	255612 ³		254677	255544	254407	255796
			256706		254721	255591		
					255538	255652		
					255650	255709		
					255830	256281		
					256234			
					256822	253179 ⁴		

¹Toxicity increase since initial screening.

²Bottle Number: BL19593

³Bottle Number: BL19584

⁴MTD= 250 mg/kg

decreased from 150mg/kg to 100mg/kg and for WR-3689 the MTD changed from 1200 to 1000mg/kg. The toxicity of WR-267614 increased from 37.5 to 18.75 mg/kg.

5. Radioprotection Screening:

Out of the thirty-six compounds (excluding WR-2721) which were received for testing of their radioprotective potential 22% afforded 100% protection against radiation induced death (see Table 11). Three of these drugs were submitted by Ash Stevens Inc., two were synthesized by F.I. Carroll and one came each from J.C. Piper, A.L. Ternay and Lamar Field respectively. Two agents (5%), one of which was a sulfinate containing compound prepared by L. Field and the well documented compound WR-3689 submitted by Klayman/Scoville protected ninety percent of the test animals. Seven drugs accounting for 19% of the submissions, four of which were obtained from the laboratory of F. I. Carroll, two from Lamar Field and one from A. L. Ternay lead to 80% survival in irradiated animals. A survival rate of 70% was obtained with two drugs; one was submitted by Ash Stevens, Inc. the other by C. Piper. A sulfinate compound from L. Field and one amidinium containing drug synthesized by L. Bauer and one agent from F. I. Carroll yielded 60% protection. The remaining fourteen drugs (39%) from several different synthesis groups produced radioprotection of 50% or less. The detailed data of the radiation protection screens for all drugs are presented in Table 12.

A. Ash Stevens, Inc.

From the compounds submitted by this synthesizer, WR-255591 (the free thiol of WR-3689) a new drug which has never been tested before, proved to be an excellent radioprotector, yielding 100% protection from a lethal radiation dose at all three drug dose levels (300, 150 and 75 mg/kg) tested. A dose modification study is in progress using this protector has been performed and is discussed elsewhere.

The methylated analog of WR-2721 compound WR-151327 exhibited 100% protection at the MTD of 600mg/kg and at one half

TABLE 11
WR DRUGS AND THEIR RESULTANT PERCENT SURVIVAL
(9.0¹ Gy and 9.5 Gy)

Submitter	100	90	80	70	60	50	40-30	20-10	0
A. Stevens	1065 ²			1065 ²					255549
	151327 ²			254677					
	255591 ¹								
F. I. Carroll	254638		254721		257614				
	254676		255830						
			256281						
			256706						
Lamar Field	256822	255542	253179		255541	255650		255544	
			255652						
James C. Piper	255538 ¹			255758			255709 ¹		257172
							257623		
A. Ternay	254407 ¹		255612 ³			256107	255612 ⁴	254844	
							256234		
L. Bauer					254593	254353			
W. O. Foye							254115		
Klayman Scoville		3689 ²							
Sigma Corp.								15443	255796
Southwest Res. Inst.									

¹ Screen performed with 9.0 Gy. ² Screen performed with both 9.0 and 9.5 Gy.

TABLE 12
RADIOPROTECTION SCREEN

WR	BN	DOSE ¹ (mg/kg)	VEHICLE	ROUTE	RADIATION DOSE (Gy)	THIRTY DAY SURVIVORS	PERCENT SURVIVAL
NONE					9.5	0/30 0/12 0/15	0 0 0
1065	BK 71365	150 75 37.5	Water	i.p.	9.0	9/10 10/10 1/10	90 100 10
1065	BK 71365	150 75 37.5	Water	i.p.	9.5	7/10 6/10 0/10	70 60 0
3689	BN 62848	1200 600 300	Water	i.p.	9.0	9/10 9/10 10/10	90 90 100
3689	BN	1200 600 300	Water	i.p.	9.5	2/10 ⁴ 9/10 9/10	20 90 90
15443	BL 09435	600 300 150	Water	i.p.	9.5	2/10 2/10 3/10	20 20 30

TABLE 12 (cont)

RADIOPROTECTION SCREEN

WR	BN	DOSE ¹ (mg/kg)	VEHICLE	ROUTE	RADIATION DOSE (Gy)	THIRTY DAY SURVIVORS	PERCENT SURVIVAL
151327	BK 98991	600 300 150	Water	i.p.	9.0	10/10 10/10 7/10	100 100 70
253179	BL 26909	250 125 62.5	H ₂ O	i.p.	9.5	8/10 7/10 1/10	80 70 10
254115	ZP 55243	9.38 4.69 2.35	see ²	i.p.	9.5	3/10 3/10 0/10 30 30 0	
254353	ZP 55289	18.75 9.38 4.69	see ²	i.p.	9.5	5/10 6/10 2/10	50 60 20

TABLE 12(cont)

RADIOPROTECTION SCREEN

WR	BN	DOSE ¹ (mg/kg)	VEHICLE	ROUTE	RADIATION DOSE (Gy)	THIRTY DAY SURVIVORS	PERCENT SURVIVAL
254407	ZP 54399	600 300 150	Water	i.p.	9.0	10/10 8/10 1/10	100 80 10
254593	ZP 55305	37.5 18.75 9.38 4.69	see ²	i.p.	9.5	0/10 6/10 2/10 0/10	0 ⁴ 60 20 0
254638	ZP 55467	300 150 75	Water	i.p.	9.5	10/10 4/10 1/10	100 40 10
254676	BL 08830	150 75 37.5	see ²	i.p.	9.5	10/10 7/10 1/10	100 70 10
254677	BL 08778	150 75 37.5	Water	i.p.	9.5	7/10 0/10 0/10	70 0 0

TABLE 12 (cont)

RADIOPROTECTION SCREEN

WR	BN	DOSE ¹ (mg/kg)	VEHICLE	ROUTE	RADIATION DOSE (Gy)	THIRTY DAY SURV. VORS	PERCENT SURVIVAL
254721	BL 09346	150 75 37.5	see ²	i.p.	9.5	8/10 5/10 3/10	80 50 30
254844	BL 10849	37.5 18.75 9.38	DMSO	i.p.	9.5	2/10 2/10 2/10	20 20 20
255538	BK 40404	150 75 37.5	see ³	i.p.	9.0	10/10 2/10 4/10	100 20 40
255541	BK 40468	100 50 25	Water	i.p.	9.5	6/10 2/10 0/10	60 20 0
255542	BK 40477	300 150 75	Water	i.p.	9.5	9/10 4/10 2/10	90 40 20

TABLE 12(cont)

RADIOPROTECTION SCREEN

WR	BN	DOSE ¹ (mg/kg)	VEHICLE	ROUTE	RADIATION DOSE (Gy)	THIRTY DAY SURVIVORS	PERCENT SURVIVAL
255544	BK 40486	300 150 75	Water	i.p.	9.5	2/10 1/10 0/10	20 10 0
255549	BK 40780	1200 600 300	Water	i.p.	9.5	0/10 0/10 0/10	0 0 0
255591	BL 24405	300 150 75	Water	i.p.	9.0	10/10 10/10 10/10	100 100 100
255612	BL 19593	50 25 12.5	DMSO	i.p.	9.5	6/10 7/10 8/10	60 ⁴ 70 80
255612	BL 19584	75 37.5 18.75	DMSO	i.p.	9.5	0/10 3/10 4/10	0 ⁴ 30 40
255650	BL 20176	150 75 37.5	Water	i.p.	9.5	5/10 2/10 0/10	50 20 0

TABLE 12(cont)

RADIOPROTECTION SCREEN

WR	BN	DOSE ¹ (mg/kg)	VEHICLE	ROUTE	RADIATION DOSE (Gy)	THIRTY DAY SURVIVORS	PERCENT SURVIVAL
255652	BL 20167	450 225 112.5	Water	i.p.	9.5	8/10 7/10 0/10	80 70 0
255709	BK 75176	300 150 75	Water	i.p.	9.0	3/10 1/10 2/10	30 10 20
255759	BL 21520	200 100 50	Water	i.p.	9.5	7/10 5/10 0/10	70 50 0
255796	BL 21997	1200 600 300	Water	i.p.	9.5	0/10 0/10 0/10	0 0 0
255830	BL 22358	150 100 75 37.5	Water	i.p.	9.5	3/10 8/10 2/10 0/10	30 ⁴ 80 20 0

TABLE 12(cont)

RADIOPROTECTION SCREEN

WR	BN	DOSE ¹ (mg/kg)	VEHICLE	ROUTE	RADIATION DOSE (Gy)	THIRTY DAY SURVIVORS	PERCENT SURVIVAL
256107	BL 26892	75 37.5 18.88	Water	i.p.	9.5	5/10 1/10 0/10	50 10 0
256234	BL 27915	150 75 37.5	Water	i.p.	9.5	5/10 2/10 0/10	50 20 0
256281	BL 28529	300 150 75	Water	i.p.	9.5	8/10 6/10 4/10	80 60 40
256706	BL 34205	75 37.5 18.75	Water	i.p.	9.5	8/10 6/10 0/10	80 60 0
256822	BL 38123	150 75 37.75	Water	i.p.	9.5	10/10 3/10 4/10	100 30 40
257172	BL 43955	18.75 9.38 4.69	Water	i.p.	9.5	0/10 0/10 0/10	0 0 0

TABLE 12(cont)

RADIOPROTECTION SCREEN

WR	BN	DOSE ¹ (mg/kg)	VEHICLE	ROUTE	RADIATION DOSE (Gy)	THIRTY DAY SURVIVORS	PERCENT SURVIVAL
257614	BL 49073	37.5 25 18.75 9.38	Water	i.p.	9.5	0/10 0/10 5/10 6/10	0 ⁴ 0 ⁴ 50 60
257623	BL 49242	100 50 25	Water	i.p.	9.5	4/10 3/10 1/10	40 30 10

¹3% Methyl Cellulose, 0.4% Tween-80, 15% Ethanol. ²0.3% Methyl Cellulose, 15% Ethanol. ³5% Sodium Bicarbonate. ⁴Toxicity related death.

MTD. Seventy percent survival was achieved with the dose of 150 mg/kg at 9.0 Gy. This compound was retested at 9.5 Gy and 100% survival was achieved for all three doses. The well examined protector WR-1065 afforded 90; 100 and 10% protection when tested at 150; 75 and 37.5mg/kg at a radiation dose of 9.0 Gy. However, only 70; 60 and 0% survival was noted at the higher dose of 9.5 Gy.

Of the two other drugs from the same submitter WR-254677, which yields WR-1065 and cysteine, and WR-255549, WR-1065 oxidized to the sulfinic acid, only WR-254677 provided 70% protection at the MTD of 150mg/kg. No effect was seen at the lower drug doses. The agent WR-255549 revealed no protective potential at all.

B. F.I.Carroll

Two compounds synthesized by F.I.Carroll exhibited good protection at the highest administered doses. Drug WR-254638 a congener of WR-2721 led to 100; 40 and 10% survival, while with WR-254676, an amidine analog of WR-3689 animal survival was 100; 70 and 10%. The other analogs of WR-3689; WR-254721, WR-255830, WR-256281 and the amidino analogue of WR-2721, WR-257706, all afforded 80% protection at the highest tested drug doses but only 50%, 20%, 60% and 60% respectively at one-half MTD. WR257614 (a rather toxic drug) led to 60% survival administered at the MTD.

C. Lamar Field

A total of seven compounds from this submitter were screened during the contract period. Of these agents one, WR-256822 afforded 100% protection at the MTD of 150 mg/kg. The disulfide containing drug WR-255542 led to 90% survival while two other sulfinic acid compounds (WR-253179 and WR-255652) yielded both 80% protection at 250 and 450 mg/kg respectively. Two other agents WR-255541 and WR-255650 resulted in 60 and 50% survival. WR-255544 had a negligible of 10-20% on survival.

D. A.L.Ternay

Six drugs came from the laboratory of this

synthesizer. The L-cysteine cysteamine disulfide WR-254407 led to 100; 80 and 10% survival for the three tested drug doses. The two other compounds, WR-256107 (which hydrolyzes to cysteamine and WR-1065) and WR-256234 (which yields WR-1065 and β -mercaptoethanol) proved to have only moderate protective capabilities. With both drugs only 50% of the irradiated test animals survived. WR-255612 was tested from two different batches. One batch (BL-19593) yielded 80% protection at 1/4 MTD (12.5 mg/kg). At MTD and 0.5 MTD there appeared to be a synergistic effect between radiation and drug toxicity, since survival rate was reduced. Further studies are required to explain this phenomenon. A different batch of the same compound (BL-19584) yielded only 40% protection at 1/4 MTD. An androsteryl-containing drug (WR-254844) led to only 20% increase in survival.

E. J.C. Piper

Five protective agents were submitted by J.C.Piper. With the Phosphorothioate WR-255538 100% protection at the highest dose was achieved, while WR-255758 protected 70% of the test animals. From the remaining agents, two namely, WR-255709, a thiazolidin containing drug, and WR-257623 provided very marginal (30% and 40%) protection respectively. WR-257172 demonstrated no protective potential.

F. Ludwig Bauer

The drugs prepared by this submitter were WR-254593 and WR-254353. These compounds are Adamantyl-amidinium containing agents with a covered thiol function. With both drugs, which are rather toxic, a moderate survival rate of 60 and 50% was achieved at the MTDs of 18.75mg/kg.

G. Others

The remaining compounds were submissions from different synthesizers. The known protector WR-3689, the methyl analog of WR-2721 was prepared by Klayman/Scoville and was tested at irradiation doses of 9.0 and 9.5 Gy. In both screens this compound afforded 90% animal survival at all three dose levels.

W.O.Foye submitted WR-254115 a compound that revealed only minimal protection (30%) as did the Sodium -Ketoglutarate from Sigma Company, which had shown activity against cyanide challenge. A submission from Southwest Research Institute (WR-255796) is non toxic but shows no ability to reduce the effectiveness of ionizing radiation.

6. Dose Modification Factor Determination:

In addition to WR-2721 (which is reported above), dose modification factors were determined for WR-3689 and WR-255591 at equimolar with WR-2721 (500 mg/kg base). The LD50(30) after treatment with WR-3689 was found to be 21.84 Gy which results in a DMF of 2.76. WR-255591, which is the dephosphorylated WR-3689 gave a LD50(30) of 18.93 Gy for a DMF of 2.40. Tables 13 and 14 present salient data on these two protectors.

TABLE 13
Thirty Day Lethality in WR-3689 Protected Mice

Dose (Gy)	n	Lethality	Percent
Exp 87-33			
19.10	10	0	0
20.24	10	2	20
21.46	10	4	40
22.74	10	7	70
LD ₅₀ (30) = 21.84 ± 1.01 Gy		Linearity = 99.66%	

TABLE 14
Thirty Day Lethality in WR-255591 Protected Mice

Dose (Gy)	n	Lethality	Percent
Exp 87-32			
17.00	10	1	10
18.02	9	2	22
19.10	9	3	30
20.24	10	7	70
21.46	10	9	90
22.74	8	8	100
LD ₅₀ (30) = 18.93 ± 0.31 Gy		Linearity = 99.86%	

CONCLUSIONS

1. The screening procedures were developed and tested with new investigators and a new mouse strain. The results obtained, with previously tested compounds appeared to be in agreement with data reported in the past.

2. The lethal dose to 50% of CD1 female mice was found to be 7.83 Gy. The gastrointestinal LD₅₀ was found to be 12.77 Gy.

3. The optimal time of injection for WR-2721 was found to be between 5 to 90 minutes prior to irradiation.

4. In addition to WR-2721 the following drugs protected mice from the LD₅₀(30) when administered at the maximum tolerated dose: WR-1065, WR-151327, WR-254638, WR-254676, WR-254407, WR-255538, WR-256822 and WR-255591.

5. WR-255591 showed 100% protection from the LD₁₀₀ dose at the MTD, 0.5 MTD and 0.25 MTD.

PUBLICATIONS

1. C. P. Sigdestad, D.J. Grdina, A.M. Connor and W.R. Hanson, A Comparison of Radioprotection from Three Neutron Sources and Cobalt-60 by WR-2721 and WR-151327. Radiat. Res. 106:224-233 (1986).
2. J. S. Zhang, C.P. Sigdestad, M.A. Gemmell and D. J. Grdina, Modification of Radiation Response in Mice by Fractionated Extracts of Panax ginseng. Radiat. Res. 112:156-163 (1987).
3. C. P. Sigdestad, K. Weber Doak and D. J. Grdina, Differential Protection of Radiation Induced DNA Single Strand Breaks and Cell Survival by Solcoseryl. Experientia (in press).

ACKNOWLEDGMENTS

During the majority of this contract year, Dr. Gerald McCormick was the Contracting Officer's Representative. He provided technical guidance with helpful discussion and suggestions. His untimely death was sincerely felt by all of us.

The author is indebted to COL David Davidson and to Doctor L. Fleckenstein for the helpful discussions during their site visit and throughout the contract year. We are indebted to LTC J. Berman for his assistance as COR. In addition, the expert assistance of Dr. Karola Doak is appreciated.

DISTRIBUTION

5 Copies

Director
Walter Reed Army Institute of Research
Walter Reed Army Medical Center
ATTN: SGRD-UWZ-C
Washington, D.C. 20307-5100

1 Copy

Commander
U.S. Army Medical Research
and Development Command
ATTN: SGRD-RMI-S
Fort Detrick
Frederick, MD 21701-5012

2 Copies

Defense Technical Information Center
ATTN: DTIC-DDAC
Cameron Station
Alexandria, VA 22304-6145

1 Copy

Dean
School of Medicine
Uniformed Services University
of Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814-4799

1 Copy

Commandant
Academy of Health Sciences, US Army
ATTN: AHS-CDM
Fort Sam Houston, TX 78234-6100